BRIEF published on 05/11/2026 at 08:05, 2 months 29 days ago Pentixapharm Submits IND to FDA for Phase 3 PANDA Study Pentixapharm Precision Diagnostics FDA IND Submission Phase 3 PANDA Cardiovascular Imaging
PRESS RELEASE published on 05/11/2026 at 08:00, 2 months 29 days ago Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism Pentixapharm IND Submission Phase 3 PANDA Study CXCR4-targeted Cardiovascular Diagnostic
BRIEF published on 05/07/2026 at 08:05, 3 months 2 days ago Point sur le développement financier et clinique de Pentixapharm au premier trimestre 2026 Résultats Financiers Développement Clinique Gestion Des Coûts Produits Radiopharmaceutiques Commentaires Réglementaires
BRIEF published on 05/07/2026 at 08:05, 3 months 2 days ago Pentixapharm Q1 2026 Financial and Clinical Development Update Financial Results Clinical Development Radiopharmaceuticals Cost Management Regulatory Feedback
PRESS RELEASE published on 05/07/2026 at 08:00, 3 months 2 days ago Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Pentixapharm Holding AG reports Q1 2026 financial results, highlights progress in clinical and regulatory activities, and provides full-year financial guidance Financial Results Regulatory Pentixapharm Q1 2026 Clinical
BRIEF published on 03/31/2026 at 08:05, 4 months 9 days ago Pentixapharm Holding AG nomme Erik Merten au conseil d'administration Conseil D'administration Produits Radiopharmaceutiques Pentixapharm Erik Merten Programme PANDA
BRIEF published on 03/31/2026 at 08:05, 4 months 9 days ago Pentixapharm Holding AG Appoints Erik Merten to Executive Board Executive Board Radiopharmaceuticals Pentixapharm Erik Merten PANDA Program
PRESS RELEASE published on 03/31/2026 at 08:00, 4 months 9 days ago Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Pentixapharm Holding AG appoints Erik Merten as Chief Technology Officer (CTO) to enhance radiopharmaceutical development and manufacturing capabilities, supporting Phase 3 PANDA program and future commercialization Executive Board Radiopharmaceuticals Pentixapharm Holding AG Erik Merten Phase 3 PANDA Program
BRIEF published on 03/19/2026 at 10:19, 4 months 21 days ago Pentixapharm Holding AG to Reveal 2025 Financial Results Conference Call Clinical Trials Pentixapharm Radiotherapeutics 2025 Financial Results
BRIEF published on 03/19/2026 at 10:19, 4 months 21 days ago Pentixapharm Holding AG publiera ses résultats financiers pour 2025 Conférence Téléphonique Essais Cliniques Pentixapharm Radiothérapie Résultats Financiers De 2025
Published on 08/07/2026 at 23:15, 2 days 6 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 6 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 2 days 6 hours ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 2 days 7 hours ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/10/2026 at 04:30, 57 minutes ago ZPMC Ships Topside Module for China's First Lightweight Integrated Offshore Substation
Published on 08/10/2026 at 04:25, 1 hour 2 minutes ago ZPMC Holds Keel-Laying Ceremony for Second LDA Service Operation Vessel
Published on 08/10/2026 at 04:20, 1 hour 7 minutes ago LINDIAN ACQUIRES REMAINING 49% INTEREST FOR 100% OWNERSHIP IN SARECO OPERATING HYDROMET FACILITY
Published on 08/10/2026 at 00:05, 5 hours 22 minutes ago Games of the Future Astana 2026 Comes to a Close After 12 Electric Days of Competition
Published on 08/09/2026 at 15:05, 14 hours 22 minutes ago GearUP and Escape from Tarkov Partner to Enhance Online Gaming Experience for the New Season
Published on 08/07/2026 at 18:54, 2 days 10 hours ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 2 days 10 hours ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 2 days 10 hours ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 2 days 10 hours ago Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 2 days 11 hours ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026
